APA (7th ed.) Citation

Marsh, R. A., Lane, A., Mehta, P. A., Neumeier, L., Jodele, S., Davies, S. M., & Filipovich, A. H. (2016). Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine,and melphalan RIC HCT. Blood, 127(4), 503. https://doi.org/10.1182/blood-2015-07-659672

Chicago Style (17th ed.) Citation

Marsh, Rebecca A., Adam Lane, Parinda A. Mehta, Lisa Neumeier, Sonata Jodele, Stella M. Davies, and Alexandra H. Filipovich. "Alemtuzumab Levels Impact Acute GVHD, Mixed Chimerism, and Lymphocyte Recovery Following Alemtuzumab, Fludarabine,and Melphalan RIC HCT." Blood 127, no. 4 (2016): 503. https://doi.org/10.1182/blood-2015-07-659672.

MLA (9th ed.) Citation

Marsh, Rebecca A., et al. "Alemtuzumab Levels Impact Acute GVHD, Mixed Chimerism, and Lymphocyte Recovery Following Alemtuzumab, Fludarabine,and Melphalan RIC HCT." Blood, vol. 127, no. 4, 2016, p. 503, https://doi.org/10.1182/blood-2015-07-659672.